← Latest papers
📄 respiratory medicine

Timing the Target: Exploring the Circadian Transcriptome of Biologic Therapies in Asthma.

This study demonstrates that a significant majority of asthma therapeutic targets, including receptors and cytokines for approved biologics, exhibit diurnal rhythmicity, suggesting that optimizing dosing times based on circadian expression peaks could enhance treatment efficacy and minimize side effects.

Original authors: Akenroye, A., Carey, V. J., Scheer, F. A. J. L., Weiss, S. T.

Published 2026-11-19 (v2)
📖 5 min read🧠 Deep dive

Original authors: Akenroye, A., Carey, V. J., Scheer, F. A. J. L., Weiss, S. T.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

For centuries, people have noticed that asthma does not behave the same way at all hours. Those who suffer from the condition often find their breathing becomes most difficult in the middle of the night or just before dawn, a pattern so consistent it has a name: nocturnal asthma. This daily fluctuation is not merely a matter of lying down or sleeping; it is driven by an internal biological clock that ticks inside nearly every cell of the human body. This clock, known as the circadian rhythm, regulates when genes turn on and off, dictating the timing of immune responses, hormone release, and inflammation. Because the body's defense systems and the chemicals that trigger asthma attacks follow this 24-hour schedule, the severity of the disease rises and falls with the sun.

In recent years, doctors have developed powerful new medicines called biologics to treat severe asthma. These are specialized drugs designed to block specific proteins or receptors that fuel the inflammation causing the disease. While these treatments have helped many, they do not work perfectly for everyone, and some patients still struggle to control their symptoms. A lingering question has been whether the timing of these doses matters. If the body's immune targets are naturally more active at certain times of day, perhaps giving the medicine when those targets are at their peak would make the treatment more effective. To answer this, researchers set out to map the daily rhythm of the very genes that these drugs are designed to hit.

A team of scientists, led by researchers at Brigham and Women's Hospital and Harvard Medical School, decided to look directly at the genetic instructions inside human blood cells to see if they change over the course of a day. They gathered data from several existing studies where healthy volunteers had been sampled repeatedly over a full 24-hour cycle, sometimes as frequently as every two hours. By analyzing the genetic activity in these samples, the team focused on forty-six specific genes. These genes were not chosen at random; they represent the exact targets of the current generation of asthma drugs, including the receptors that catch allergy signals and the proteins that drive inflammation.

The researchers first confirmed that their methods worked by checking the behavior of the body's master clock genes. They found that the majority of these internal timekeepers were indeed swinging up and down in a predictable rhythm, peaking at specific times. This gave them confidence to look at the asthma-related genes. The results were striking. Of the genes they could measure across multiple groups of people, nearly three-quarters showed a clear, significant daily rhythm. This means that the very targets these drugs are meant to block are not static; they rise and fall in intensity throughout the day.

Among the genes that showed this daily pattern were those involved in the most common types of asthma inflammation. The study identified that genes controlling the body's response to allergens, such as the receptor for IgE antibodies, peaked in the late night or early morning. Other targets, including the receptor for a protein called IL-5, which is central to a different type of asthma inflammation, showed a peak in the early morning hours. The researchers also found that genes involved in the body's broader immune signaling, which are blocked by other modern asthma therapies, followed their own distinct schedules. Some peaked in the afternoon, while others surged in the early morning.

The consistency of these findings across different groups of people suggests that this daily variation is a fundamental part of human biology, not just a fluke of one specific study. The team noted that while the genes did not all peak at the same time, their rhythms were reliable enough to be mapped with precision. For instance, the gene for the high-affinity IgE receptor, which is the target of a drug called omalizumab, reached its highest levels around midnight. In contrast, the gene for the IL-5 receptor, targeted by a drug called benralizumab, peaked around 8:00 AM. These specific timings suggest that the body's vulnerability to these specific pathways changes as the day progresses.

The study did not test whether changing the time of a dose actually improved patient outcomes, so it cannot yet tell doctors exactly when to prescribe these medicines. However, the discovery that these targets are rhythmically active provides a strong scientific basis for asking that question. It suggests that the effectiveness of a drug might depend on whether it is given when its target is most abundant or most active. The researchers point out that other chronic inflammatory diseases, such as rheumatoid arthritis, have already benefited from timing treatments to match the body's natural cycles.

By revealing that the molecular targets of asthma biologics are not constant but instead dance to a daily beat, this work opens a new door for optimizing treatment. It implies that the current standard of giving these drugs at a fixed time might be missing an opportunity to align therapy with the body's own internal clock. While more research is needed to determine the best schedule for each specific medication, the study confirms that the timing of asthma treatment is a factor worth investigating. The findings suggest that in the future, managing severe asthma may involve not just choosing the right drug, but also choosing the right moment to give it.

Drowning in papers in your field?

Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.

Try Digest →